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Introduction
Since the first lung transplantation was performed in 1963, 
this approach has become an effective treatment method for 
end-stage lung disease of various causes (1,2). The number 
of annual lung transplantations has rapidly increased 
compared to the past although the number of heart-lung 
transplantations is steady or somewhat declining worldwide. 
Most lung transplantations have been mainly conducted in 
North America and Europe (3). The survival rate associated 
with lung transplantation increased in the 2000s compared 
to the 1990s. And a large proportion of deaths after lung 
transplantation occurred within a year. The median 
survival of adult recipients is 4–6 years, and, especially, the 
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median survival of recipients who survived for >1 year after 
transplantation is 7.9 years with good prognosis (3). Because 
the prognosis of recipients who survived for 1 year is very 
good, some researchers have reported the risk factors for 
predicting 1-year mortality after lung transplantation (4,5). 
Although the results were controversial, old age, application 
of preoperative extracorporeal membrane oxygenation 
(ECMO), decreased kidney function before the operation 
and preoperative diabetes mellitus were reported to affect 
the prognosis of 1-year morality (4-6). Furthermore, recent 
study showed that the age of lung transplant recipients is 
increasing recently and the 3-year survival rate is lower 
in advanced recipients, especially age 65 or older than in 
younger age group (7).
The first lung transplantation in Korea was performed 
in July 1996, and a total of 284 lung transplantations, 
including heart-lung transplantations, have been performed 
until October 2015 (8-10). Although only 1 or 2 procedures 
were conducted each year until 2003, currently >50 
procedures are being performed each year (9). However, the 
lack of donated lungs and the low utilization rate of donor 
lungs from declared brain-dead patients are major problems 
associated with lung transplantation in Korea compared 
with other countries. In 2010, only 6.7% of donor lungs 
were used, which was low compared with kidney (93.3%) 
and liver (86.3%) (11). In the data of 2015 Korean Network 
of Organ Sharing (KONOS), utilization rate of donor lungs 
increased to 12.8% (64/500), it was still shortage for 120 
patients waiting for transplantation. Therefore, selection 
of appropriate recipients and prediction of prognosis are 
important for lung transplantation in Korea.
Unfortunately, most studies about the risk factors of 
1-year mortality after lung transplantation were performed 
on non-Asians (4-6). We supposed that the risk factors of 
1-year mortality after lung transplantation in Korea might 
be different from those in North America and Europe, 
which have different circumstances and cultures (8,11). 
Accordingly, we reviewed the preoperative, perioperative, 
and postoperative risk factors of 1-year mortality after lung 
transplantation in Korea.
Methods 
Study design and population
This was a retrospective cohort study on consecutive patients 
who underwent lung transplantation at a single center 
(Severance Hospital) in South Korea, from October 2012 
to October 2015. During 3 years, 81 patients received lung 
transplantation surgery. Recipients who received ECMO 
before transplantation and those who underwent re-
transplantation were excluded in order to analyze the risk 
factors in relatively stable patients.
All recipients received ECMO or cardiopulmonary bypass 
for cardiopulmonary support during transplantation surgery 
and were administered induction immunosuppression therapy 
with high dose corticosteroid using methylprednisolone 
500 mg during operation and 0.5 mg/kg/day for 3 days 
after operation. Triple immunosuppression therapy, such as 
prednisolone, tacrolimus, and mycophenolate mofetil, was 
used for maintaining immunosuppression after transplantation. 
Mycophenolate mofetil were administered 1 g daily and 
tacrolimus concentration levels on blood were maintained 
from 8 to 12 ng/mL. Valganciclovir and itraconazole were used 
all recipients until 6 months after operation. Trimethoprim/
sulfamethoxazole was used in all recipients for a lifetime to 
prevent pneumocystis jiroveci after operation. 
All donor lungs from declared brain-dead patients were 
preserved in low-potassium dextran solution (Perfadex; 
Duraent Biologicals, Hyderabad, India). The study subjects 
were divided into two groups according to their 1-year 
survival status, and various factors were analyzed.
Data collection and definition
Data from all recipients were collected from the electronic 
medical records of the hospital, and donor data were collected 
from the Korean Network of Organ Sharing (KONOS). 
Recipient data including demographic characteristics, 
laboratory results, mortality, use of mechanical ventilator while 
waiting for transplantation, length of stay at the intensive care 
unit, and other clinical data were evaluated. Furthermore, 
donor data including demographic characteristics, ischemic 
time, and hospital stay duration were investigated.
Smoking status was defined as either ever smoker or 
never smoker (smoked <100 cigarettes during the lifetime). 
Mean pulmonary artery pressure was measured by means 
of right heart catheterization before transplantation. 
Primary graft dysfunction (PGD) was defined by consensus 
according to the International Society for Heart and Lung 
Transplantation (ISHLT) (12). Acute kidney injury (AKI) 
was defined as increase in serum creatinine by ≥0.3 mg/dL 
within 48 h or increase in serum creatinine to 30% 
more than the baseline value during 1 month after lung 
transplantation (13). Delta neutrophil index (DNI) which 
reflects the fraction of circulating immature granulocytes 
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and associate with sepsis was measured preoperatively and 
at 24–48 h by using an automatic cell analyzer (ADVIA 
2120 Hematology System; Siemens Healthcare Diagnostics, 
Forchheim, Germany) (14-16). The change of DNI was 
defined as the difference between preoperative DNI 
value and the highest DNI value 48h after surgery. Bone 
marrow density was calculated by using dual-energy X-ray 
absorptiometry to screen for osteopenia. Osteopenia was 
defined a T score of −1.0 or lower in those aged ≥50 years 
and a Z score of −1.0 or lower in those aged <50 years. Use 
of immunosuppressive agents before transplantation was 
defined as taking any immunosuppressive medication, such 
as prednisolone, mycophenolate mofetil, or azathioprine, 
regardless of dose or type.
Statistical analysis
All data that were represented as continuous or categorical 
variables were analyzed with SPSS version 23 (IBM, 
Armonk, NY, USA). Continuous data were presented as 
median with range or interquartile range. These variables 
were evaluated by using the Mann-Whitney U test for the 
difference between two groups. The chi-square and Fisher’s 
exact tests were used to assess differences in categorical 
variables, presented as number and percentage, between 
the two groups. The cut-off value of change in DNI 
before and after surgery according to 1-year mortality 
was determined using receiver operating characteristic 
(ROC). The independent risk factors for 1-year mortality 
after lung transplantation were identified by using logistic 
regression modeling that included significant variables 
in univariate analysis or basic clinical characteristics (17). 
The Kaplan-Meier method was used to create survival 
curves of meaningful variables, and statistical analysis of 
survival curves was performed using the log-rank test (18). 
In all analysis results, a P value of <0.05 was considered 
statistically significant.
Results
A total of 81 patients underwent lung transplantation during 
the study period. Among them, 12 patients were excluded 
because they received ECMO support before surgery and 1 
patient was excluded because of re-transplantation.
Baseline characteristics
Table 1 describes the baseline characteristics of recipients and 
donors. A total of 68 subjects were enrolled and analyzed 
in this study. Forty-four patients (64.7%) lived for >1 year 
after lung transplantation. The median age of all patients was 
55 years (range, 16–75 years), and male patients accounted 
for 57.4% of the total. The median follow-up duration was 
749 days (range, 391–1,478 days). The major cause of lung 
transplantation was idiopathic pulmonary fibrosis (IPF) 
(48.5%); the other causes were interstitial lung disease 
related to connective tissue disease (17.6%) and bronchiolitis 
obliterans after stem cell transplantation (14.7%).
Perioperative factors associated with 1-year mortality
In the univariate analysis of clinical factors related to 1-year 
mortality, there was no difference between the survivor and 
nonsurvivor group except age, preoperative serum albumin 
level, AKI after surgery and change in DNI before and after 
surgery.
There was a high proportion of elderly recipients 
(P<0.001) and male recipients (P=0.007) in the nonsurvivor 
group. Preoperative blood sampling showed a high 
proportion of albumin level <3 g/dL in the nonsurvivor 
group (P=0.049). The occurrence of AKI after surgery was 
significantly high in the nonsurvivor group (P=0.008) and, 
especially, the need for renal replacement therapy (RRT) 
showed a more significant difference between the two 
groups (P=0.001). The change in DNI before and after 
surgery were more increased in the nonsurvivor group, 
and the proportion of recipients whose postoperative 
DNI increased by >5.5 which was derived through ROC 
(sensitivity, 70.8%; specificity, 77.3%) compared with the 
preoperative DNI was higher in the nonsurvivor group than 
in the survivor group (P<0.001). In the univariate analysis 
of donors, there was no difference between the two groups 
except the smoking status (P=0.04).
Independent risk factors were evaluated through 
multivariate analysis of variables that showed meaningful 
results in the univariate analysis and baseline variables (Table 2). 
The results of the analysis revealed that age 55–65 years 
[odds ratio (OR), 9.69; 95% confidence interval (CI), 
1.68–55.77], age >65 years (OR, 146.02; 95% CI, 7.95–
2,681.47), postoperative DNI >5.5 higher than preoperative 
DNI (OR, 11.66; 95% CI, 1.94–70.12), and need for RRT 
after surgery (OR, 14.01; 95% CI, 1.44–136.67) were the 
independent perioperative risk factors for 1-year mortality 
after lung transplantation.
Figure 1 presents the Kaplan-Meier survival estimates 
of groups classified according to age, postoperative 
4009Journal of Thoracic Disease, Vol 9, No 10 October 2017
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2017;9(10):4006-4016jtd.amegroups.com
Table 1 Baseline characteristics and clinical factors related with 1-year mortality
Variables Survivor (N=44) Nonsurvivor (N=24) Total (N=68) P value
Recipients 
Age, year, median [range] 52 [16–75] 61.5 [17–73] 55 [16–75] <0.001
Age group (years), n (%) <0.001
≤55 32 (72.7) 5 (20.8) 37 (54.4)
55< Age ≤65 11 (25.0) 12 (50.0) 23 (33.8)
>65 1 (2.3) 7 (29.2) 8 (11.8)
Male sex, n (%) 20 (45.5) 19 (79.2) 39 (57.4) 0.007
Follow up duration, median day (range) 759 [391–1,478] 700 [431–1,411] 749 [391–1,478] 0.739
Bilateral lung transplantation, n (%) 41 (93.2) 20 (83.3) 61 (89.7) 0.233
Height, cm, median (range) 164 [147–175] 167 [141–175] 165 [141–175] 0.724
BMI, kg/m2, median (range) 19.4 (12.4–27.3) 20.3 (15.5–27.4) 19.8 (12.4–27.4) 0.281
BMI category, n (%) 0.666
BMI <18.5 16 (36.4) 7 (29.2) 23 (33.8)
18.5≤ BMI <23 19 (43.2) 9 (37.5) 28 (41.2) 
23≤ BMI <25 5 (11.4) 4 (16.7) 9 (13.2)
25≤ BMI <30 4 (9.1) 4 (16.7) 8 (11.8)
Pre OP MV, n (%) 6 (13.6) 6 (25.0) 12 (17.6) 0.321
Ever smoker, n (%) 19 (43.2) 15 (62.5) 34 (50.0) 0.128
Osteopenia, n (%)* 33 (82.5) 15 (75.0) 48 (80.0) 0.511
Pre OP HCT <35%, n (%) 10 (22.7) 8 (33.3) 18 (26.5) 0.343
Pre OP albumin <3 g/dL, n (%) 10 (22.7) 11 (45.8) 21 (30.9) 0.049
Pre OP FEV1, %, median (range)
† 41 (12–56.0) 47 [17–106] 41.5 [12–106] 0.291
Pre OP FVC, %, median (range)† 41 (13.9–68) 42 [16–83] 41 (13.9–83) 0.321
Pre OP DM, n (%) 10 (22.7) 7 (29.2) 17 (25.0) 0.558
Pre OP cardiovascular disease, n (%) 4 (9.1) 3 (12.5) 7 (10.3) 0.691
Post OP Cr, mg/dL, median (range) 0.62 (0.32–0.94) 0.64 (0.24–2.48) 0.62 (0.24–2.48) 0.484
MPA, mmHg, median [range]‡ 25.5 [9–49] 22.5 [14–43] 25 [9–49] 0.143
MPA >25‡ 17 (50.0) 4 (28.6) 21 (43.8) 0.174
MPA >35‡ 6 (17.6) 1 (7.1) 7 (14.6) 0.656
Use of immunosuppressive agents 27 (61.4) 14 (58.3) 41 (60.3) 0.807
Use of prednisolone dose ≥20 mg, n (%) 5 (11.4) 6 (25.0) 11 (16.2) 0.177
Post OP AKI, n (%) 13 (29.5) 15 (62.5) 28 (41.2) 0.008
Post OP RRT, n (%) 2 (4.5) 9 (37.5) 11 (16.2) 0.001
Post OP re-operation, n (%) 10 (22.7) 8 (33.3) 18 (26.5) 0.343
Post OP DNI change, median (IQR) 3.35 (1.88–5.48) 7.70 (2.83–11.38) 4.60 (2.20–7.93) 0.002
Table 1 (continued)
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Table 1 (continued)
Variables Survivor (N=44) Nonsurvivor (N=24) Total (N=68) P value
Post OP DNI increasing >5.5, n (%) 10 (22.7) 17 (70.8) 27 (39.7) <0.001
Length of ICU, median days (IQR) 8.5 (5–15.5) 8 (6–19.5) 8 (5.3–16.8) 0.515
Length of Hospital, median days (IQR) 31 (23.3–50.5) 38 (24.5–99.8) 32.5 (24–58.3) 0.342
PGD =3, n (%) 4 (9.1) 1 (4.2) 5 (7.4) 0.649
Cause of lung transplantation 0.156
COPD/emphysema 0 (0) 1 (4.2) 1 (1.5)
IPF 17 (38.6) 16 (66.7) 33 (48.5)
Idiopathic pulmonary HTN 0 (0) 1 (4.2) 1 (1.5)
Pulmonary fibrosis, other 2 (4.5) 0 (0) 2 (2.9)
Bronchiectasis 3 (6.8) 1 (4.2) 4 (5.9)
BO after SCT 7 (15.9) 3 (12.5) 10 (14.7)
Connective tissue disease 10 (22.7) 2 (8.3) 12 (17.6)
LAM 3 (6.8) 0 (0) 3 (4.4)
Other§ 2 (4.5) 0 (0) 2 (2.9)
Donor
Age, years, median (range) 45 [12–59] 45 [21–59] 45 [12–59] 0.484
Age ≥50 years, n (%) 13 (29.5) 9 (37.5) 22 (32.4) 0.503
Height, cm, median (range) 166 [145–182] 169 [150–178] 167 [145–182] 0.463
BMI, kg/m2, median (range) 22.7 (17.4–35.32) 22.4 (19.4–32.05) 22.7 (17.4–35.3) 0.949
Ever smoker, n (%)‖ 19 (44.2) 15 (71.4) 34 (53.1) 0.040
ICU stay days, median (range) 6 [2–21] 5.5 [2–12] 6 [2–21] 0.708
Lung ischemic time, min, median (range) 233 [112–470] 240 [143–451] 238 [112–470] 0.984
Bacterial growth in BAL culture, n (%) 27 (61.4) 11 (45.8) 38 (55.9) 0.218
Donor height < recipient height, n (%) 21 (47.7) 10 (41.7) 31 (45.6) 0.632
Sex mismatch between donor and  
recipient, n (%)
16 (36.4) 5 (20.8) 21 (30.9) 0.185
BMI, body mass index; OP, operation; MV, mechanical ventilation; HCT, hematocrit; FEV1, forced expiratory volume in 1 second; FVC, 
forced vital capacity; DM, diabetic mellitus; Cr, creatinine; MPA, mean pulmonary artery pressure; AKI, acute kidney injury; RRT, renal 
replacement therapy; DNI, delta neutrophil index; ICU, intensive care unit; IQR, interquartile range; PGD, Primary graft dysfunction; COPD, 
chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; HTN, hypertension; BOS, Bronchiolitis obliterans; SCT, stem 
cell transplantation; LAM, lymphangioleiomyomatosis; BAL bronchoalveolar lavage. *, 8 missing values; †, 7 missing values; ‡, 20 missing 
values; §, chronic hypersensitivity pneumonitis, destroyed lung; ‖, 4 missing values
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DNI >5.5 higher than preoperative DNI, and need for RRT 
after surgery. All graphs reached statistical significance in 
the log-rank test (P<0.001).
Subgroup analysis of lung transplantation in patients 
We conducted subgroup analysis according to age because 
there might be differences in the baseline characteristics 
between age groups. Between patients aged ≤65 years (n=60) 
and those aged >65 years (n=8), we did not find a difference 
other than proportion of bilateral lung transplantations 
(96.7% vs. 37.5%, P<0.001) and the prevalence of diabetes 
mellitus (20% vs. 62.5%, P=0.02).
Figure 1 showed the biggest survival difference between >55 
and ≤55 years age groups, therefore, we further analyzed the 
characteristics of subjects between >55 and ≤55 years age groups 
(Table 3). Bilateral lung transplantations were performed more 
frequently in the ≤55 years age group than in the >55 years 
age group (P=0.041), and the prevalence of diabetes mellitus 
was higher in the >55 years age group (P=0.003). Predicted 
forced vital capacity and forced expiratory volume in 
1 second before transplantation were higher in the >55 years 
age group.
Subgroup analysis of the perioperative risk factors for 
1-year mortality after lung transplantation in patients 
according to age groups in the >55 and ≤55 years age 
groups was performed. 
In >55 years age group, 31 patients were >55 years 
Table 2 Independent risk factors of 1 year mortality after lung 
transplantation
Variable OR 95% CI P value
Male sex 0.87 0.15–4.92 0.871
Albumin <3 mg/dL 1.73 0.31–9.62 0.530
Age group (years)
≤55 Reference Reference Reference
55< Age ≤65 9.69 1.68–55.77 0.011
>65 146.02 7.95–2,681.47 0.001
DNI >5.5 11.66 1.94–70.12 0.007
Post OP AKI 0.98 0.17–5.69 0.981
Post OP RRT 14.01 1.44–136.67 0.023
OR, odds ratio; CI, confidence interval; DNI, delta neutrophil 
index; AKI, acute kidney injury; RRT, renal replacement therapy.
Figure 1 Survival rates of groups classified according to age, 
changes in delta neutrophil index (DNI), and the need for renal 
replacement therapy (RRT).
≤55
55<  Age ≤65
Log-rank P <0.001
>65
Age groupe group
 Age ≤65
Survival days
0            200         400          600          800        1000        1200        1400
S
ur
vi
va
l r
at
e
1.0
0.8
0.6
0.4
0.2
0.0 Log-rank p <0.001
Survival days
0            200         400          600          800        1000        1200        1400
S
ur
vi
va
l r
at
e
1.0
0.8
0.6
0.4
0.2
0.0
≤5.5
>5.5
Log-rank P <0.001
P ost op  D N I increasing
5.5
5.5
ost op DNI increasing
Log-rank p <0.001
W ithout R R T
W ith  R R T
Log-rank P <0.001
P ost op  R R Tst op RRT
ithout RRT
ith R T
g-rank p <0.001
0            200         400          600          800        1000        1200        1400
Survival days
S
ur
vi
va
l r
at
e
1.0
0.8
0.6
0.4
0.2
0.0
4012 Lee et al. Risk factors for 1-year mortality after LTx
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2017;9(10):4006-4016jtd.amegroups.com
Table 3 Clinical characteristics according to age group
Variables Age ≤55 (N=37) Age >55 (N=31) Total (N=68) P value
Recipients 
Age, years, median [range] 44 [16–55] 60 [57–75] 55 [16–75] <0.001
Male sex, n (%) 16 (43.2) 23 (74.2) 39 (57.4) 0.010
Follow up duration, median day (range) 782 [391–1,478] 671 [400–1,411] 749.5 [391–1,478] 0.353
Bilateral lung transplantation, n (%) 36 (97.3) 25 (80.6) 61 (89.7) 0.041
Height, cm, median (range) 165 [147–175] 165 [141–175] 165 [141–175] 0.412
BMI, kg/m2, median (range) 19 (12.4–27.3) 21 (15.5–24.4) 19.8 (12.4–27.4) 0.050
BMI category, n (%) 0.045
BMI <18.5 13 (35.1) 10 (32.3) 23 (33.8)
18.5≤ BMI <23 19 (51.4) 9 (29.0) 28 (41.2) 
23≤ BMI <25 4 (10.8) 5 (16.1) 9 (13.2)
25≤ BMI <30 1 (2.7) 7 (22.6) 8 (11.8)
Pre OP MV, n (%) 5 (13.5) 7 (22.6) 12 (17.6) 0.329
Ever smoker, n (%) 14 (37.8) 20 (64.5) 34 (50.0) 0.028
Osteopenia, n (%)* 29 (87.9) 19 (70.4) 48 (80.0) 0.092
Pre OP HCT <35%, n (%) 9 (24.3) 9 (29.0) 18 (26.5) 0.661
Pre OP albumin <3 g/dL, n (%) 10 (27.0) 11 (35.5) 21 (30.9) 0.452
Pre OP FEV1, %, median (range)
† 29.5 [12–64] 57 [19–106] 41.5 [12–106] <0.001
Pre OP FVC, %, median (range)† 33 (13.9–70) 46 [22–83] 41 (13.9–83) 0.002
Pre OP DM, n (%) 4 (10.8) 13 (41.9) 17 (25.0) 0.003
Pre OP cardiovascular disease, n (%) 3 (8.1) 4 (12.9) 7 (10.3) 0.694
Post OP Cr, mg/dL, median (range) 0.6 (0.32–0.94) 0.65 (0.24–2.48) 0.62 (0.24–2.48) 0.190
MPA, mmHg, median (range)‡ 25 [9–49] 24.5 [16–43] 25 [9–49] 0.925
MPA >25‡ 15 (53.6) 10 (50.0) 25 (52.1) 0.807
MPA >35‡ 6 (21.4) 2 (10.0) 8 (16.7) 0.295
Use of immunosuppression 24 (64.9) 17 (54.8) 41 (60.3) 0.400
Use of prednisolone dose (range) (%) 5 (13.5) 6 (19.4) 11 (16.2) 0.515
Post OP AKI, n (%) 13 (35.1) 15 (48.4) 28 (41.2) 0.269
Post OP RRT, n (%) 4 (10.8) 7 (22.6) 11 (16.2) 0.189
Post OP re-operation, n (%) 11 (29.7) 7 (22.6) 18 (26.5) 0.506
Post OP DNI change, median (IQR) 4.6 (2.0–7.2) 5.3 (2.2–9.9) 4.6 (2.2–7.9) 0.270
Post OP DNI increasing >5.5, n (%) 12 (32.4) 15 (48.4) 27 (39.7) 0.181
Length of ICU, median days (IQR) 9 [5–17] 8 [6–16] 8 (5.3–16.8) 0.762
Length of Hospital, median days (IQR) 33 (24.5–50) 32 [20–87] 32.5 (24–58.3) 0.810
PGD =3, n (%) 4 (10.8) 1 (3.2) 5 (7.4%) 0.366
Table 3 (continued)
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Table 3 (continued)
Variables Age ≤55 (N=37) Age >55 (N=31) Total (N=68) P value
Cause of lung transplantation, n (%) <0.001
COPD/emphysema 0 (0) 1 (3.2) 1 (1.5)
IPF 9 (24.3) 24 (72.7) 33 (48.5)
Idiopathic pulmonary HTN 1 (2.7) 0 (0) 1 (1.5)
Pulmonary fibrosis, other 1 (2.7) 1 (3.2) 2 (2.9)
Bronchiectasis 2 (5.4) 2 (6.5) 4 (5.9)
BO after SCT 10 (27.0) 0 (0) 10 (14.7)
Connective tissue disease 9 (24.3) 3 (9.7) 12 (17.6)
LAM 3 (8.1) 0 (0) 3 (4.4)
Other§ 2 (5.4) 0 (0) 2 (2.9)
BMI, body mass index; OP, operation; MV, mechanical ventilation; HCT, hematocrit; FEV1, forced expiratory volume in 1 second; FVC, 
forced vital capacity; DM, diabetic mellitus; Cr, creatinine; MPA, mean pulmonary artery pressure; AKI, acute kidney injury; RRT, renal 
replacement therapy; DNI, delta neutrophil index; ICU, intensive care unit; IQR, interquartile range; PGD, Primary graft dysfunction; COPD, 
chronic obstructive pulmonary disease; IPF, idiopathic pulmonary fibrosis; HTN, hypertension; BOS, Bronchiolitis obliterans; SCT, stem 
cell transplantation; LAM, lymphangioleiomyomatosis; BAL bronchoalveolar lavage; *, 8 missing values; †, 7 missing values; ‡, 20 missing 
values; §, chronic hypersensitivity pneumonitis, destroyed lung.
old and 12 patients (38.7%) survived for >1 year after 
transplantation. Need for RRT (0% vs. 36.8% P=0.026), 
and postoperative DNI >5.5 higher than preoperative 
DNI (25% vs. 63.2%, P=0.038) were significantly related 
to 1-year mortality after lung transplantation in patients 
>55 years old. 
In ≤55 years age groups, 37 patients were ≤55 years old and 
32 patients (86.5%) survived for >1 year after transplantation. 
The occurrence of AKI after surgery (28.1% vs. 80%, 
P=0.042), need for reoperation (21.9% vs. 80%, P=0.021) 
and postoperative DNI >5.5 higher than preoperative 
DNI (21.9% vs. 100%, P=0.002) were significantly related 
to 1-year mortality after lung transplantation in patients 
≤55 years old. Meanwhile, there was no significant difference 
in other variables including sex, height or body mass index 
of recipients, use of mechanical ventilation while waiting 
for transplantation, smoking experience, preoperative 
lung function, mean pulmonary artery pressure before 
transplantation, use of immunosuppressive agents before 
transplantation, and development of PGD grade 3.
Outcome
The median survival of nonsurvivors was 111.5 days 
(interquartile range, 62.5–161.3). The most common cause 
of death was infection (n=14, 58.3%), followed by cardiac 
arrest (n=3, 12.5%) and thrombotic microangiopathy 
(n=3,  12.5%).  Some pat ients  died in  associat ion 
with hemophagocytic lymphohistiocytosis, ischemic 
cholangiopathy, or bleeding. The number of recipients who 
were >65 years old was 8, and only 1 recipient among them 
survived for >1 year after lung transplantation and sepsis 
was major cause of death (n=5, 71.4%). 
Among nonsurvivors, only 2 patients died within 30 days 
after transplantation due to sepsis without evidence of 
primary graft failure. Bacteria such as Methicillin-resistant 
Staphylococcus aureus, Enterococcus faecium, Pseudomonas 
aeruginosa or multidrug-resistant Acinetobacter baumannii 
grew in blood culture of 9 patients among infection 
patients. Four patients died due to pneumonia which 
occurred at least 5 months after transplantation except 1 
patient. The same bacteria as results of BAL of donor lung 
were cultured in blood of 3 patients, which were considered 
donor-acquired infection. 
Discussion
In this study, we investigated the independent risk factors 
for 1-year mortality after lung transplantation. Old age 
was identified as the only preoperative predictive factor 
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for 1-year mortality. Postoperative DNI >5.5 higher than 
preoperative DNI and the need for RRT after surgery 
were revealed as postoperative predictive factors of 1-year 
mortality.
Several studies have reported on the risk factors or 
predictors of mortality after lung transplantation (4-6,19-22). 
However, most of those studies were performed in North 
America and Europe, and the environment and causes of 
lung transplantation in Korea are slightly different. Such 
differences could affect the predictors and risk factors 
of mortality after lung transplantation. For example, the 
major causes of lung transplantation in the ISHLT registry 
were chronic obstructive pulmonary disease/emphysema 
(32.1%), IPF (24.1%), and cystic fibrosis (16.2%). On the 
other hand, IPF (48.5%), interstitial lung disease related 
to connective tissue disease (17.6%), and bronchiolitis 
obliterans after stem cell transplantation (14.7%) were the 
main causes of lung transplantation in our hospital (3). 
In Korea, there are very few patients with cystic fibrosis 
compared to other countries and only one patient with 
cystic fibrosis received lung transplant from 2010 to 2014 
(9,23). Furthermore, the registration in KONOS for 
patients waiting for transplantation was relatively late, and 
the mortality rate while waiting for lung transplantation 
in Korea was higher than in other countries. We supposed 
that late referral may be due to a pessimistic attitude of 
patients and physicians regarding its high mortality of early 
transplantation era. And priority of transplantation is given 
patients with ventilator or ECMO support in Korea (24-26). 
Therefore, IPF patients with acute exacerbation who 
needed for ventilator or ECMO support have a higher 
priority than waiting patients with stable condition.
An upper age limit for recipient selection has not been 
established. However, age >65 years has been considered a 
relative contraindication for lung transplantation (27,28). 
Nevertheless, as the elderly population increased, lung 
transplantation in elderly patients also increased (3). 
Tomaszek et al. reported that patients aged >60 years did 
not seem to show significantly poor outcome during short-
term and long-term follow-up (19). However, Weiss et al. 
reported that lung transplantation might be performed 
with caution in patients older than 60 years but not in those 
older than 70 years (22). Our study showed that elderly 
recipients of lung transplantation in Korea had a worse 
prognosis than those in other countries. Because there 
might be differences in the baseline characteristics between 
age groups, we conducted an analysis. As a result, we did not 
find a difference other than in the type of transplantation, 
the prevalence of diabetes mellitus and major cause of 
transplantation. Generally, recipients of bilateral lung 
transplantation revealed a better median survival than those 
with single lung transplantation (3), and the mortality of 
patients with IPF and those with diabetes mellitus was 
reported to be higher than that of patients with other 
underlying lung diseases (3,6). Therefore, we supposed that 
these factors could be associated with high mortality in the 
old-age group.
AKI after lung transplantation developed in 37%, and 
the incidence of RRT was 5.51% in some previous studies 
(29,30). The prevalence of AKI and RRT in our data 
were higher than in previous reports (41.2% and 16.2%, 
respectively), the finding in our study that the need for 
RRT after lung transplantation increased mortality was 
similar to previous reports (29,30). Several studies have 
shown the reasons for the high risk of AKI in recipients 
of lung transplantation; for example, lung injury could 
induce inflammatory mediators of the renal epithelium, 
nephrotoxic agents including calcineurin inhibitors could 
induce direct injury, and efforts to maintain negative 
balance might cause kidney injury after transplantation. 
Furthermore, some studies suggested that patients with 
AKI, particularly those requiring RRT, were at an increased 
risk of mortality (29-32). However, the reason for increased 
mortality with the need for RRT is unclear. Importantly, 
the need for RRT after surgery could be considered a state 
of critical illness.
Increased DNI is known to be associated with sepsis and 
disseminated intravascular coagulation (33,34). However, 
the relationship between DNI and the prognosis after 
surgery is not well known. Our data showed that the 
changes in DNI before and after transplantation were 
different between the two groups, and that increasing 
of DNI values >5.5 especially could predict the 1-year 
mortality after lung transplantation. The standard DNI 
value of 5.5 was derived through ROC and this value was 
similar to those of previous studies associated with sepsis 
and DNI (33,34). Our data showed that the cause of death 
for 14 of 24 recipients (58.3%) who died within 1 year 
after transplantation was infection. And increasing of DNI 
values >5.5 was found in 11 of 14 (78.6%) patients who 
died within 1 year after transplantation. We hypothesized 
that patients with increased DNI are likely to be vulnerable 
to infection. An environment that promotes exposure to 
various pathogens and the increased proportion of elderly 
patients with lower physical ability among candidates for 
lung transplantation may be factors affecting this result.
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Our study has several limitations. This was a relatively 
small study performed at a single center. However, this 
was the first study on the mortality of lung transplantation 
in Korea. Most previous studies were performed in 
North America and Europe, and their results are difficult 
to generalize on account of racial and environmental 
differences. Therefore, this study will be helpful in 
understanding lung transplantation in Asians. Second, 
this study had a retrospective design; thus, we could not 
systemically analyze multiple laboratory test results, 
perioperative factors, and preoperative performances. 
However, we believe that because lung transplantation is 
increasingly being conducted in Korea, this problem will be 
overcome through further studies in the future.
Conclusions
Advanced age in recipients of lung transplantation is 
associated with 1-year mortality after lung transplantation. 
Therefore, candidates for lung transplantation with 
advanced age should be carefully selected. The need for 
RRT and increased DNI after transplantation are also 
associated with 1-year mortality after lung transplantation; 
therefore, attention should be paid to patients with a 
possibility of having AKI and increased DNI, to improve 
their survival.
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